Concord Biotech Limited has announced its unaudited financial results for the first quarter and year ended June 30, 2026. The company reported a revenue from operations of ₹25,748.90 lakhs for the quarter, with a profit after tax of ₹5,769.69 lakhs. The financial results were reviewed by the Audit Committee and approved by the Board of Directors.
Concord Biotech Declares Q1 FY27 Financial Results
Concord Biotech Limited has disclosed its unaudited consolidated financial results for the first quarter ended June 30, 2026, and the full financial year ended the same date. The Board of Directors approved these results following a review by the Audit Committee. These figures provide insights into the company’s financial performance during the specified periods.
Key Financial Highlights (Consolidated)
For the quarter ended June 30, 2026, Concord Biotech reported total income of ₹27,031.49 lakhs. Expenses for the period amounted to ₹19,324.91 lakhs, leading to a profit before tax of ₹7,706.58 lakhs. After accounting for tax expenses of ₹2,064.62 lakhs, the profit after tax attributable to owners of the company stood at ₹5,769.69 lakhs. Total comprehensive income for the period was ₹7,475.83 lakhs.
Year-End Performance
For the financial year ended June 30, 2026, the company’s total income reached ₹1,10,724.60 lakhs. Total expenses for the year were ₹76,223.26 lakhs, resulting in a profit before tax of ₹34,501.34 lakhs. After tax expenses of ₹8,541.81 lakhs, the profit after tax for the year was ₹25,922.91 lakhs. The total comprehensive income for the year was ₹31,447.27 lakhs.
Standalone Financials
On a standalone basis, the company reported revenue from operations of ₹26,051.71 lakhs for the quarter ended June 30, 2026. Expenses for the standalone results were ₹19,140.39 lakhs, yielding a profit after tax of ₹6,119.37 lakhs. For the full financial year, standalone revenue from operations was ₹1,05,507.10 lakhs, with a profit after tax of ₹26,326.67 lakhs.
Acquisition of Celliimune Biotech Private Limited
The company also noted that Celliimune Biotech Private Limited, incorporated on January 15, 2025, was acquired by Concord Biotech Limited on April 02, 2026. Consequently, Celliimune Biotech Private Limited is now a wholly-owned subsidiary.
Source: BSE
